Denosumab and Associated Biosimilars for Non-Oncologic Indications
Customize your policy alerts
Sign up for healthspring Policy RX501.140 alerts
Get alerted when Policy RX501.140 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity coverage of Prolia (denosumab) and FDA-approved denosumab biosimilars for adults with postmenopausal osteoporosis, osteoporosis in men, or glucocorticoid-induced osteoporosis. Oncologic indications are addressed under a separate HealthSpring policy.
FDA-approved language was added to the medically necessary coverage statement and Note 2.
Denosumab-adet (Ponlimsi) was added to the biosimilars identified in Note 2.
Coverage criteria for glucocorticoid-induced osteoporosis were revised.
Additional denosumab biosimilars were added to the identified products.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.